Steven Cohen Cellectis S.A. Transaction History

Point72 Asset Management, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$7.81 - $18.82 $333,393 - $803,388	-42,688 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$9.73 - $19.31 $1.42 Million - $2.83 Million	-146,312 Reduced 77.41%	42,688 $731,000
Q3 2019 Nov 15, 2019	BUY	$10.15 - $16.89 $471,975 - $785,385	46,500 Added 32.63%	189,000 $1.97 Million
Q2 2019 Aug 14, 2019	BUY	$14.6 - $20.6 $833,660 - $1.18 Million	57,100 Added 66.86%	142,500 $2.22 Million
Q1 2019 May 15, 2019	SELL	$15.53 - $19.75 $4.89 Million - $6.21 Million	-314,600 Reduced 78.65%	85,400 $1.57 Million
Q4 2018 Feb 14, 2019	BUY	$15.58 - $28.41 $3.8 Million - $6.93 Million	243,867 Added 156.19%	400,000 $6.66 Million
Q3 2018 Nov 14, 2018	BUY	$25.99 - $30.6 $2.2 Million - $2.59 Million	84,533 Added 118.06%	156,133 $4.41 Million
Q2 2018 Aug 14, 2018	BUY	$27.78 - $38.53 $44,448 - $61,648	1,600 Added 2.29%	71,600 $2.03 Million
Q1 2018 May 15, 2018	BUY	$27.78 - $35.19 $1.94 Million - $2.46 Million	70,000 New	70,000 $2.21 Million

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71.9M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.